MiMARK
MIMARK is dedicated to caring for women’s health by developing innovative in vitro diagnostic solutions to improve the management of gynecological diseases. Their mission is to advance gynecological diagnostics, with a focus on improving endometrial cancer diagnosis through their proprietary immunoassay, WomEC. They aim to transform gynecological care by providing highly accurate, minimally invasive diagnostic tools that reduce patient discomfort and healthcare costs.
Industries
Nr. of Employees
small (1-50)
Products
IVD immunoassay for endometrial cancer diagnosis using uterine fluid
An in vitro diagnostic immunoassay that quantifies a panel of protein biomarkers in uterine fluid collected by minimally invasive endometrial aspiration to aid diagnosis of endometrial cancer in post‑menopausal women with abnormal uterine bleeding.
IVD immunoassay for endometrial cancer diagnosis using uterine fluid
An in vitro diagnostic immunoassay that quantifies a panel of protein biomarkers in uterine fluid collected by minimally invasive endometrial aspiration to aid diagnosis of endometrial cancer in post‑menopausal women with abnormal uterine bleeding.
Services
Collaborative development and clinical validation partnerships
Partnerships for co-development, clinical validation and commercialization of assay prototypes and diagnostic workflows using gynecological fluid biomarkers.
Collaborative development and clinical validation partnerships
Partnerships for co-development, clinical validation and commercialization of assay prototypes and diagnostic workflows using gynecological fluid biomarkers.
Expertise Areas
- In vitro diagnostic development
- Biomarker discovery and verification
- Targeted proteomics for biomarker verification
- Immunoassay (ELISA) development
Key Technologies
- Targeted mass spectrometry (LC-PRM)
- ELISA and immunoassay platforms
- Antibody reagent generation
- Biobanking and sample preservation